Black Diamond Therapeutics nabs $85 mln Series B
Black Diamond Therapeutics Inc, a biotechnology company developing next-generation precision medicines for cancer, has closed $85 million in Series B financing. New Enterprise Associates and RA Capital Management led the round with participation from NexTech Invest, The Invus Group, Perceptive Advisors and Versant Ventures.
10 January 2019•1 min read
